Berger really fumbled the FDA shutdown of Ponatinib. There were clear signs of SAE issues and the management team, led by Harvey, miscalculated the FDA response. That indicated to me that he is not a smart manager and is not equipped to bring true value to the stock. Intelligence doesn't equate to business savvy or people skills. Hope he leaves when he sees the fight for control is a losing battle.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.